These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21868521)

  • 1. Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells.
    Arao T; Matsumoto K; Furuta K; Kudo K; Kaneda H; Nagai T; Sakai K; Fujita Y; Tamura D; Aomatsu K; Koizumi F; Nishio K
    Anticancer Res; 2011 Sep; 31(9):2787-96. PubMed ID: 21868521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells.
    Meissner M; Reichenbach G; Stein M; Hrgovic I; Kaufmann R; Gille J
    Cancer Res; 2009 Mar; 69(5):1976-84. PubMed ID: 19223539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
    Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
    Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
    Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt.
    Imai N; Shikami M; Miwa H; Suganuma K; Hiramatsu A; Watarai M; Satoh A; Itoh M; Imamura A; Mihara H; Nitta M
    Br J Haematol; 2006 Dec; 135(5):673-82. PubMed ID: 17107349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma.
    Das B; Yeger H; Tsuchida R; Torkin R; Gee MF; Thorner PS; Shibuya M; Malkin D; Baruchel S
    Cancer Res; 2005 Aug; 65(16):7267-75. PubMed ID: 16103078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taspine downregulates VEGF expression and inhibits proliferation of vascular endothelial cells through PI3 kinase and MAP kinase signaling pathways.
    Zhao J; Zhao L; Chen W; He L; Li X
    Biomed Pharmacother; 2008; 62(6):383-9. PubMed ID: 17826025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of VEGF isoforms and VEGF(164)-specific receptor neuropilin-1 in the mouse uterus suggests a role for VEGF(164) in vascular permeability and angiogenesis during implantation.
    Halder JB; Zhao X; Soker S; Paria BC; Klagsbrun M; Das SK; Dey SK
    Genesis; 2000 Mar; 26(3):213-24. PubMed ID: 10705382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.
    Zhang L; Hannay JA; Liu J; Das P; Zhan M; Nguyen T; Hicklin DJ; Yu D; Pollock RE; Lev D
    Cancer Res; 2006 Sep; 66(17):8770-8. PubMed ID: 16951193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
    Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel role of ARF6 in vascular endothelial growth factor-induced signaling and angiogenesis.
    Ikeda S; Ushio-Fukai M; Zuo L; Tojo T; Dikalov S; Patrushev NA; Alexander RW
    Circ Res; 2005 Mar; 96(4):467-75. PubMed ID: 15692085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers.
    Gunningham SP; Currie MJ; Morrin HR; Tan EY; Turley H; Dachs GU; Watson AI; Frampton C; Robinson BA; Fox SB
    J Pathol; 2007 Jul; 212(3):335-44. PubMed ID: 17487938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
    Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
    Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.
    Deroanne CF; Bonjean K; Servotte S; Devy L; Colige A; Clausse N; Blacher S; Verdin E; Foidart JM; Nusgens BV; Castronovo V
    Oncogene; 2002 Jan; 21(3):427-36. PubMed ID: 11821955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y; Wang S; Hoot DR; Clinton SK
    J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.